Fig. 4From: Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitisChronic phase glibenclamide reduces inflammation and improves the macrophage phenotype in EAE. White matter of lumbar spinal cord sections from non-EAE control (CTR), untreated EAE mouse (EAE), and EAE mouse treated with glibenclamide starting on pid-24 (EAE + G), examined at pid-40, immunolabeled for p65 (NF-κB subunit), GFAP (astrocytosis), CD86 (M1 marker) or CD163 (M2 marker), as indicated; original magnification, × 400; bar graphs: quantification of p65+, GFAP, CD86+, and CD163+ cells in white matter; 5 mice/group; ## P < 0.01 with respect to non-EAE control (CTR); *P < 0.05 and **P < 0.01 with respect to untreated EAE; scale bars 100 μmBack to article page